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Myxofibrosarcoma: a diagnostic pitfall
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Abstract
Myxofibrosarcoma (MFS) is a variant of the
group of malignant fibrous histiocytomas. It is
one of the most aggressive types of soft tissue
neoplasms. The clinical presentation is not
pathognomonic and the histological aspects
are highly heterogenous, frequently delaying
the diagnosis or leading to misdiagnosis.
Complementary histochemical and immuno-
histochemical stainings are mandatory to
achieve the diagnosis of MFS. A 78-year-old
male patient is presented illustrating this
diagnostic pitfall. Extensive surgery followed
by radiotherapy is the first choice treatment.
Introduction
Malignant fibrous histiocytoma (MFH)
belongs to the heterogeneous group of fibro-
histiocytic tumors.1-4 MHF is part of soft tissue
neoplasms, composed of cells sharing fibrob-
lastic and histiocytic features. MFH is one of
the most aggressive of the group of fibrohisti-
ocytic tumors. MFH exhibits a high local
recurrence rate and a significant metastatic
rate. It is also the most frequent sarcoma
found in the adult patient.
Case Report
A 78-year-old man, without any remarkable
medical or surgical history, presented an
asymptomatic, rapidly growing, indurated and
firm nodule on the right forearm. Over two
months, the lesion had reached about 4 cm in
diameter (Figure 1). There was no previous
skin lesion and the site was never traumatized
or irradiated. A differential diagnosis of a
cutaneous metastatic lesion or a kystic lesion
was suggested. Surgical excision was per-
formed under local anesthesia with tumor
removal until the muscular fascia. The
histopathologic picture showed a well-defined,
well-limited large nodular lesion located in the
subcutaneous fat tissue composed of a dense
pleomorphic-storiform cellular infiltrate.
There were numerous round, fusiform and
stellate tumor cells with undefined cell mar-
gins, eosinophilic cytoplasms and hyperchro-
matic atypical nuclei. Immunohistochemical
staining revealed that the tumor cells were
positive for vimentin and p63, but negative for
CK-7 (low molecular-weight cytokeratins),
CK-20 (high molecular-weight cytokeratins),
CD117, actin, protein S100a and HMB45, sug-
gesting a metastatic adenocarcinoma. The
deep surgical margins were free of tumor
involvement.  
The patient was hospitalized for searching
the initial tumor. A total body scan, a PET-
scanner and an extensive blood test were all
negative. Tumor markers were negative. IRM
imaging of the involved arm revealed no resid-
ual tumor or further tissue invasion. Facing
the absence of a primary tumor, a second opin-
ion on the histology of the initial tumor tissue
was requested. Other immunohistochemical
markers revealed a strong positive signal for
CD99 and alpha-anti-trypsin whereas desmin,
pancytokeratin, EMA, CD68 and factor XIII-a
remained negative. These findings were sug-
gestive of MFH. Furthermore, the presence of
extensive myxoid matrix changes containing
elongated curvilinear capillaries (Figures 2
and 3) as revealed by the PAS-iron colloidal
histochemical stain favored a diagnosis of a
myxoid variant of MFH, also called myxofi-
brosarcoma (MFS). 
As the surgical margins were free of tumor
involvement and as the IRM imaging present-
ed no further particularities, the pluridiscipli-
nar cutaneous oncology group recommended
strict clinical surveillance but no complemen-
tary radiotherapy.
Three months later, at a control visit, the
patient presented two new smaller asympto-
matic firm nodular lesions in the immediate
vicinity of the previous surgical scar (Figure
4). These lesions were again surgically
removed under local anesthesia. Histology
revealed again a myxoid variant of MFH.
There was an invasion of the deep surgical
margins. Subsequently, a large surgical re-
excision was performed including removal of
the fascia. A PETSCAN excluded the presence
of suspect locoregional lymphadenopathies.
Du to the rapid occurrence of the MFS recur-
rence, it was decided to perform complemen-
tary radiotherapy (25 sessions). Up to date,
the patient is recurrence free and has no func-
tional disability of his arm. 
Discussion and Conclusions
Fibrohistiocytic tumors represent a highly
heterogeneous group of soft tissue neoplasms
composed of cells exhibiting fibroblastic and
histiocytic features.1,3,5 MFH is one of the most
common soft tissue tumors in adult
patients.1,3,6 MFH also exhibits a very aggres-
sive loco-regional behavior, with a high risk
for local recurrence and a significant metasta-
tic rate.4 MFH is usually classified as superfi-
cial or deep tumor. The superficial variant typ-
ically presents as a painless, progressively
enlarging single nodule. Tumor growth may
occur over several months, sometimes reach-
ing 5 to 10 cm in size at the time of diagnosis.
Superficial MFH is also known as atypical
fibroxanthoma. It shows a more favorable
prognosis than others type. Any area of the
body may be involved but the most common
sites are the extremities. 
Several other subtypes of MFH are
described in the literature including the pleo-
morphic, the myxoid, the giant cell, the
inflammatory and the angiomatoid variants.
The myxoid type, also known as myxofibrosar-
coma (MFS), is the second most frequent sub-
type, representing approximately 20% of cases
and is characterized by an association of myx-
oid areas and cellular areas in variable propor-
tions.7-9 They are among the most frequent
malignant mesenchymal tumors of the elder-
ly.4,8,9 The mean age is 66 years and the sex
ratio is 1:1.4 The extremities are the most
common site followed by the trunk, the pelvis,
the head and neck region and the genital
area.4 The most frequent initial presentation
is a single cutaneous asymptomatic nodule.10
The deep dermis and hypodermis are the pref-
erential sites and represent about 2/3 of the
cases of MFS. The abundance of myxoid areas
defines the lesion’s grade, being more promi-
nent in lower-grade lesions. The differential
diagnosis should exclude benign myxoid neo-
plasms, epitheloid types of MFS, carcinoma,
melanoma, myoepithelial carcinoma, pleomor-
phic liposarcoma and pleomorphic rab-
domyosarcoma.11
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As illustrated in this case, not only the clin-
ical diagnosis but also the histopathologic
identification can be very difficult.8 One paper
related 3 cases of myxofibrosarcoma that were
initiallyl diagnosed as benign cutaneous neo-
plasms.8 Final diagnosis relies on a large
series of histochemical and immunohisto-
chemical staining.11,12 Immunohistochemistry
typically stains positive for only vimentin and
occasionally actin.12 DNA flow cytometry
reveals an association between aneuploidy
and histologic grading. Local recurrence
occurs in about 50% of the patients with MFS.
Distant metastasis occurred in 13/60 patients
and death was attributed to MFS in 13/60
cases.4 Metastasis only occurred in patients
exhibiting intermediate or high grade MFS.
MFS typically behaves more aggressively if
recurrent lesions appear.4
Large resection represents the first choice
of treatment.4,8 Surgical excision has to be as
large as possible as MFH may spread over a
considerable distance beyond the gross tumor
margins. Insufficient tumor-free margins are
the open door to local recurrence, and hence a
worse prognosis.
Due to the high recurrence and metastatic
rate of MFH, adjuvant radiation therapy is rec-
ommended to treat eventual occult local micro
metastases. Metastatic sites are essentially
pulmonary and lymphatic.
The prognosis of MFH seems to correlate
with four principal features. The increasing
depth of tumor invasion is the most predictive
for the risk of metastatic disease. The size of
the tumor (smaller than 5 cm versus greater
than 5 cm), the anatomical location (distally
versus proximally located tumors) and the his-
tological features (including the degree of
anaplasia and the number of mitoses) also
correlate with prognosis.4,8
The follow-up of MFS patients should be
very thorough to manage properly eventual
local recurrences. 
In conclusion, MFH is a great clinical mim-
icker and may present a histologic nightmare.
A large series of histochemical and immuno-
histochemical stainings is recommended.
Extensive surgical excision with adjuvant
radiotherapy presents the optimal therapeutic
option. 
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Case Report
Figure 1. Primary tumoral lesion on the
right forearm.
Figure 2. Histologic examination of the pri-
mary lesion (Haematoxylin and Eosin, x 20). 
Figure 3. Histologic examination of the pri-
mary lesion (Haematoxylin and Eosin, x 40).
Figure 4. Two small recurring lesions adja-
cent to the initial surgical excision.
